Published 12 days ago • loading... • Updated 11 days ago

What will pharma's share buyback shopping spree mean for M&A?

Summary by Endpoints News

A handful of cash-rich pharma companies have announced billions of dollars in share buybacks in recent months, raising questions about their interest in transformative dealmaking this year. Eli Lilly, GSK, Merck, Regeneron and Sanofi have ...

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All

Left

Center

Right

European Pharmaceutical Manufacturer

Meaningful Integration: Building culture and success in pharma M&A

After the pharmaceutical industry’s muted mergers and acquisitions (M&A) landscape in 2024, Nick Petschek, EMEA MD at Kotter International suggests many expect M&A to pick back up in 2025.

11 days ago

Read Full Article